Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid stimulating hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    118 result(s) found for: Thyroid stimulating hormone. Displaying page 3 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2007-007831-24 Sponsor Protocol Number: KBT-006 Start Date*: 2008-03-17
    Sponsor Name:Karo Bio AB
    Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB2115 as add on to Ezetimibe treatment in Patients with Primary...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000783-15 Sponsor Protocol Number: GP41341 Start Date*: 2019-05-07
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, TWO PART STUDY TO EXPLORE THE PERFORMANCE OF ENTRECTINIB PROTOTYPE MINI-TABLET FORMULATIONS AND THE EFFECT OF DRUG SUBSTANCE PARTICLE SIZE ON ENTRECTINIB BIOAVAILABILITY I...
    Medical condition: non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), salivary gland cancers, papillary thyroid cancer, melanoma, and sarcomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004937-15 Sponsor Protocol Number: BNC210.006 Start Date*: 2015-04-16
    Sponsor Name:BIONOMICS LIMITED
    Full Title: A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006337-27 Sponsor Protocol Number: 03140-203 Start Date*: 2009-03-24
    Sponsor Name:EPIX Pharmaceuticals, Inc.
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRX-03140 AS MONOTHERAPY IN SUBJECTS WITH ALZHEIMER’S DISEASE
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002232-16 Sponsor Protocol Number: TAK-653-2001 Start Date*: 2017-12-15
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003380-26 Sponsor Protocol Number: TCP-304 Start Date*: 2021-01-05
    Sponsor Name:Ascendis Pharma Bone Diseases A/S
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Admini...
    Medical condition: Hypoparathyroidism in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed) FR (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004594-32 Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 Start Date*: 2022-02-16
    Sponsor Name:IO Biotech ApS
    Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv...
    Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005534-38 Sponsor Protocol Number: E7080-G000-207 Start Date*: 2014-10-21
    Sponsor Name:Eisai Ltd.
    Full Title: Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma
    Medical condition: Refractory or relapsed solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) FR (Ongoing) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005374-57 Sponsor Protocol Number: Calcimimetics Start Date*: 2013-02-15
    Sponsor Name:Department of Breast and Endocrine Surgery, Karolinska University Hospital
    Full Title: Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?
    Medical condition: Primary hyperparathyroidism (PHPT) is a common disease, characterized by a high-normal calcium concentration and an inappropriately increased parathyroid hormone (PTH) level
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012598-37 Sponsor Protocol Number: DUT-MD-304 Start Date*: 2010-01-29
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUTOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON BACKGROUND TREATMENT WIT...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000488-83 Sponsor Protocol Number: P03685 Start Date*: 2004-11-29
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response
    Medical condition: Chronic Hepatitis C, Genotype 1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) HU (Completed) LT (Completed) CZ (Completed) AT (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002389-62 Sponsor Protocol Number: 8-55-52030-309 Start Date*: 2015-03-02
    Sponsor Name:Ipsen Group
    Full Title: Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of lanreotide PRF in subjects wi...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) LT (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003788-67 Sponsor Protocol Number: FS1306 Start Date*: 2014-01-29
    Sponsor Name:Watson Laboratories, Inc. - A subsidiary of Actavis, Inc.
    Full Title: A Randomised, Parallel Group, Assessor-Blind, Multicentre Study to Compare the Safety and Efficacy of Watson rhFSH with Follitropin Alfa (GONAL-f) in Stimulating Multiple Follicular Development in ...
    Medical condition: Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001615-21 Sponsor Protocol Number: B5161004 Start Date*: 2016-12-12
    Sponsor Name:Pfizer Inc.
    Full Title: A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616 in Boys with Duchenne Muscular Dystrophy
    Medical condition: Duchenne's Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001810-13 Sponsor Protocol Number: GSN000350 Start Date*: 2021-12-11
    Sponsor Name:Genkyotex Suisse SA
    Full Title: TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elev...
    Medical condition: Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) PL (Completed) IT (Completed) GR (Completed) SE (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000694-30 Sponsor Protocol Number: 01-05-TL-322OPI-001 Start Date*: 2006-09-21
    Sponsor Name:Takeda Europe Research & Development Centre Ltd.,
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type ...
    Medical condition: Type II Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-000867-24 Sponsor Protocol Number: ALFR-HC-04 Start Date*: 2005-05-23
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION...
    Medical condition: Hepatitis type C chronic
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-001969-27 Sponsor Protocol Number: GLP111892 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016051-22 Sponsor Protocol Number: CL004_140 Start Date*: 2010-02-09
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus in subjects with insufficient glycemic control on a stable dose of metformin
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-005542-38 Sponsor Protocol Number: MK-8931-019 Start Date*: 2014-03-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment...
    Medical condition: prodromal Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:49:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA